---
figid: PMC4594714__bcp0080-0765-f1
figtitle: The RAS-RAF-MEK-ERK pathway and the mechanism of action of vemurafenib,
  dabrafenib and trametinib
organisms:
- NA
pmcid: PMC4594714
filename: bcp0080-0765-f1.jpg
figlink: /pmc/articles/PMC4594714/figure/fig01/
number: F1
caption: The RAS-RAF-MEK-ERK pathway and the mechanism of action of vemurafenib, dabrafenib
  and trametinib. Oncogenic mutations in the BRAF protein cause overactivation of
  this pathway, leading to increased cell proliferation, cell survival, and angiogenesis
  (A). Vemurafenib and dabrafenib selectively inhibit mutated BRAF proteins, whereas
  trametinib inhibits MEK and downstream ERK signalling. TF, transcription factor
  (B)
papertitle: Vemurafenib/dabrafenib and trametinib.
reftext: Robert Rissmann, et al. Br J Clin Pharmacol. 2015 Oct;80(4):765-767.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9355345
figid_alias: PMC4594714__F1
figtype: Figure
organisms_ner:
- NA
redirect_from: /figures/PMC4594714__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4594714__bcp0080-0765-f1.html
  '@type': Dataset
  description: The RAS-RAF-MEK-ERK pathway and the mechanism of action of vemurafenib,
    dabrafenib and trametinib. Oncogenic mutations in the BRAF protein cause overactivation
    of this pathway, leading to increased cell proliferation, cell survival, and angiogenesis
    (A). Vemurafenib and dabrafenib selectively inhibit mutated BRAF proteins, whereas
    trametinib inhibits MEK and downstream ERK signalling. TF, transcription factor
    (B)
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - trametinib
  - dabrafenib
  - tyrosine
---
